MARGATE, N.J.--Aug. 19, 2003--GeneLink, Inc. (OTCBB:GNLK) announced it signed a distribution agreement with Enzymatic Therapy, Inc.
Enzymatic Therapy's medical practitioner division, Integrative Therapeutics Inc., is the leading supplier of clinically validated nutritional supplements to doctors and health care professionals in the United States.
Integrative Therapeutics will market GeneLink's patented DNA Collection Kit(R) and Nutragenetic Profile Assessments(TM) to its medical practitioner customers.
"These offerings underscore our commitment to deliver the highest-quality and most effective products to health care practitioners," says Enzymatic Therapy President and CEO Randy J. Rose. "GeneLink genetic assessments allow our customers to expand their services and to better help patients make important health decisions."
"We are very pleased to partner with Enzymatic Therapy to begin offering the benefits of our genetic profiling technologies to their loyal base of health care professionals," says John R. DePhillipo, Chairman/CEO of GeneLink. "This is an ideal marketing relationship for each of our companies and we look forward to the possibility of other associations within the portfolio companies. GeneLink anticipates revenues from this Agreement by the 4th Quarter of this year."
About Enzymatic Therapy:
Headquartered in Green Bay, Wis., Enzymatic Therapy manufactures more than 200 natural medicines, nutritional supplements, vitamins, and herbal extracts distributed exclusively via independent health food stores nationwide. The company's Integrative Therapeutics Inc. division focuses on the research, development and distribution of clinically-validated nutritional supplements for doctors and health care practitioners. Recognized brands include: Vitaline, Tyler Encapsulations, NF Formulas, PhytoPharmica and the newly-introduced Learner's Edge. (see: www.enzy.com; www.integrativeinc.com)
Enzymatic Therapy and Integrative Therapeutics are part of a portfolio of companies managed by North Castle Partners, LLC., the nation's leading private equity firm focused exclusively on the Healthy Living & Aging marketplace. (see: www.northcastlepartners.com)
GeneLink, Inc., a pioneer DNA banking and hereditary genetic information service has developed proprietary genetic assessments (patents pending) and is licensing its Nutragenetic and Dermagenetic Profile Assessments(TM) to manufacturers and distributors in the $100 Billion+ nutritional supplement and skin care industries.
This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.